Egfr exon 20 insertion in metastatic non-small-cell lung cancer: survival and clinical efficacy of egfr tyrosine-kinase inhibitor and chemotherapy

HIGHLIGHTS

• who: Samy Chelabi et al. from the Université, Paris, France have published the Article: EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy, in the Journal: (JOURNAL)
• what: In this period of rapid progress, the authors aim to improve the characterization of this rare population. The aim of the study was to describe EGFR Exon20ins NSCLC patients and evaluate their response to first-line historical ECGF TKIs or chemotherapy. The secondary aims of the study were to determine overall survival (OS) and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.